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Abstract
Objective: We assessed the adequacy of randomized controlled trial (RCT) registration, changes to registration data and
reporting completeness for articles in ICMJE journals during 2.5 years after registration requirement policy.
Methods: For a set of 149 reports of 152 RCTs with ClinicalTrials.gov registration number, published from September 2005
to April 2008, we evaluated the completeness of 9 items from WHO 20-item Minimum Data Set relevant for assessing trial
quality. We also assessed changes to the registration elements at the Archive site of ClinicalTrials.gov and compared
published and registry data.
Results: RCTs were mostly registered before 13 September 2005 deadline (n=101, 66.4%); 118 (77.6%) started recruitment
before and 31 (20.4%) after registration. At the time of registration, 152 RCTs had a total of 224 missing registry fields, most
commonly ‘Key secondary outcomes’ (44.1% RCTs) and ‘Primary outcome’ (38.8%). More RCTs with post-registration
recruitment had missing Minimum Data Set items than RCTs with pre-registration recruitment: 57/118 (48.3%) vs. 24/31
(77.4%) (x
2
1=7.255, P=0.007). Major changes in the data entries were found for 31 (25.2%) RCTs. The number of RCTs with
differences between registered and published data ranged from 21 (13.8%) for Study type to 118 (77.6%) for Target sample
size.
Conclusions: ICMJE journals published RCTs with proper registration but the registration data were often not adequate,
underwent substantial changes in the registry over time and differed in registered and published data. Editors need to
establish quality control procedures in the journals so that they continue to contribute to the increased transparency of
clinical trials.
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Introduction
Study publication and outcome reporting biases are two major
obstacles to evidence-based practice because they overestimate the
effect of experimental treatments, can cause harm and are
unethical [1–18]. In recent years, the transparency of clinical
trials has considerably increased with the establishment of public
clinical trial registries and legislative changes in many countries
[19–22]. An important momentum for increased transparency in
research and reporting in medicine was provided by the
International Committee of Medical Journals’ (ICMJE) in 2004,
when it put forward its policy on mandatory registration of clinical
trials as a precondition for manuscript submission [23]. The
ICMJE also contributed to the development and adopted the first
version of 20-item World Health Organization (WHO) Minimum
Data Set in 2005, making clear that the journals ‘‘will consider a
registration data set inadequate if it has missing fields or fields that
contain uninformative terminology’’ [24]. In February 2006, Item
11 ‘Research Ethics Review’ from the 20-item WHO Minimum
Data Set was changed to ‘Countries of recruitment’[25]. In 2007,
ICMJE expanded the acceptable primary registers to all those
participating in the WHO International Clinical Trials Registry
Platform (ICTRP) and implemented the WHO definition of a
clinical trial [21].
The initial ICMJE registration policy in 2004 set two deadlines
for trial registration [23]. The first deadline was 1 July 2005 – for
any clinical trial starting enrollment after that date, they had to be
registered with the full Minimum Data Set entered before the
recruitment of the first patients. The second deadline was 13
September 2005, by which time all trials that began enrollment
prior to 1 July 2005, had to be registered in order to be considered
for publication after manuscript submission.
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policy and the experience of the largest trial registry, ClinicalTrials.
gov, showed that the number of registered trials increased
dramatically around the second ICMJE deadline and kept a
steady increase since then [26]. Despite increased registration, the
completeness and quality of registered data and the reporting bias
still remain as an obstacle to trial transparency [27].
In a cross-sectional study of trials in ClinicalTrials.gov registry,
Ross et al [28] demonstrated that, while the registration of
mandatory registry data was satisfactory, the reporting of optional
data for ClinicalTrials.gov but mandatory data for ICMJE, such as
primary outcome and trial end date, was unsatisfactory. In a study
looking at randomized controlled trials (RCTs) published in 10
high-impact general and specialty medical journals [29] selective
outcome reporting was still prevalent, despite the registration of
the trials in public registries.
As these studies were performed on a general population of
registered trials and journals, it is possible that their results reflect
the fact that other journals may have not fully adopted the ICMJE
registration policy. To assess how well ICMJE member journals
followed their own registration requirement policy in the first two
years of the policy implementation [23,24] we evaluated the
completeness of 9 out of 20 WHO Minimum Data Set items,
which are relevant for assessing trial quality. We analyzed articles
reporting on RCTs in ICMJE member journals from the 13
September 2005 deadline to April 2008, registered in the largest
public trial registry at that time, ClinicalTrials.gov.A sClinicalTrials.
gov also registers all changes to RCTs records in its Archive site, we
evaluated the history of changes to the registration data elements
until the date of publication. Finally, we assessed the reporting bias
by determining the differences in the published vs. registered data.
Methods
Data sources and study period
We retrospectively identified all reports of clinical trials with
ClinicalTrials.gov registry number (NCT), published by ICMJE
journals from 13 September 2005 to 24 April 2008 (total time: 2.5
years after the second ICMJE deadline on 13 September 2005).
Reports were identified by a PubMed search using ‘ClinicalTrials.
gov [si]’ as a key word and the following limits: all individual
ICMJE journals, date range (YYYY/MM/DD) and type of article
(RCT).
ClinicalTrials.gov database was chosen for analysis because it was
one of the largest public registry of clinical trials at the time of the
first ICMJE registration policy and because it maintains an Archive
feature, which records all modifications to individual trial database
records. The Archive site was implemented on 23 June 2005 and
was open to the public from 6 October 2006 at http://
ClinicalTrials.gov/archive [30].
Sample
The criteria for including articles in the study were: 1)
presenting results of RCTs and published in an ICMJE journal
from 13 September 2005 to 24 April 2008, 2) having ClinicalTrials.
gov registration number, and 3) having visible registration data in
the Archive site of ClinicalTrials.gov (after 23 June 2005). From 482
retrieved articles, we excluded non-RCTs articles and articles
describing sub-analyses or post hoc analyses of RCTs (total
n=44). This left 438 articles from 5 large ICMJE journals with
.20 published articles and 2 journals with ,20 published articles;
other ICMJE journals did not published articles about RCTs in
the studied period. For journals with smaller volume of published
articles, we included all of them (5 in Croatian Medical Journal, Croat
Med J, and 1 in Canadian Medical Association Journal, CMAJ) and took
a random third from each of the other ICMJE journals with more
than 20 published articles (Figure 1). The randomization was
performed using random permutation of integers (available at
www.randomization.com).
Data extraction
Nine WHO Minimum Data Set items. One investigator
extracted from ClinicalTrials.gov the data for 9 out of 20 WHO
Minimum Data Set items [31]: Item 10 (‘Official scientific title
of the study – Scientific Title’), Item 12 (‘Health Condition(s) or
Problem(s) Studied’), Item 13 (Interventions), Item 14 (‘Key a)
inclusion or b) exclusion criteria’), Item 15 (‘Study type’), Item 16
(‘Anticipated trial start date – Date of First Enrollment’), Item 17
(‘Target sample size’), Item 19 (‘Primary outcome’) and Item 20
(‘Key secondary outcomes’). Data for Minimum Data Set items 1,
2, 3, 6, 7, 8, 9 and 18 were not assessed because they are either
administrative in character, expected to differ at first and last
registration, were recorded only in the recruiting period or were
not routinely published in a journal article. The definitions of the
WHO Minimum Data Set were taken from the WHO Trial
Registration Data Set (Table S1) [31]. The other investigator
verified the extraction and data entries and disagreements were
resolved by discussion. The following parameters were recorded:
1) data at first registration, 2) data at last registration modification
before publication, and 3) differences of published data to those
specified in the registration entry. As all journals did not provide
the date of manuscript submission, the date of publication was
used as the proxy for the last date of registration entry change
before article submission to a journal.
Completeness of Minimum Data Set items in the register
For data set items included in the study we identified those with:
a) missing information – defined as the data not visible in the
specified registry item, or b) with uninformative terminology –
defined as unspecified or unclear information for the relevant
registry item (e.g., a code instead of a generic name of drug for
Item 13), both at the time of the first registration and the time of
the last registration modification before publication.
Changes in the Minimum Data Set Items in the registry
We also identified Minimum Data Set items for which the
information was changed from the first to the last registration
modification prior to publication, as well as from the last
modification prior to publication and the published article. A
major modification was defined as: a) qualitative change – the
difference in the meaning of the information provided in a registry
field (e.g., addition or deletion of data items in the article vs. that in
the registry, direction of change in time, uninformative entries),
or b) quantitative change – difference in a numerical entry in a
registry field. Minor changes, such as administrative or grammat-
ical changes, were also recorded but were not included in the
analysis. Trials with a single registration point in the same register
were defined as those that had no recorded changes in the registry.
Reporting completeness of Minimum Data Set items
The definition of major modifications was the same as used for
modifications in the registry, except for primary and secondary
outcomes, for which we used a modified classification of Chan
et al. [8]: 1) primary and secondary outcome not visible in the
specified registry item; 2) registered primary outcome reported as a
secondary outcome in the published article; 3) registered primary
and secondary outcome omitted in the published article; 4) a new
ICMJE Journals and Trial Registration Policy
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article; 5) difference in the timing of assessment of the registered
and published primary and secondary outcome; and 6) the
outcome used in the power calculation not the same in the register
and the published article.
Statistical analysis
The data were presented as frequencies and percentages or
median with 95% confidence intervals (CI). Chi-square test was
used to compare missing registry data. To ensure that the random
selection of one third of the published articles did not favor any
particular period after the September 2005 deadline, possible
differences in the number of articles published in three separate
periods (Sept 2005 to Apr 2006, May 2006 to Apr 2007 and May
2007 to Apr 2008) were tested.
Results
Characteristics of RCTs from ClinicalTrials.gov and
published articles
The total sample of RCTs (n=152) included 143 randomly
selected articles from 5 ICMJE journals, describing 146 RCTs
with a unique registry identifier (NCT) in ClinicalTrials.gov and
all 6 articles (6 RCTs) from 2 ICMJE journals (Figure 1). Other
ICMJE journals did not publish reports of RCTs and were not
included in the study. To test whether the number of published
articles varied over time analyzed in the study, we compared this
number for journals with more than 20 published articles in three
arbitrary time periods between September 2005 and April 2008
and did not find any differences (x
2
2=0.009, P=0.995 for NEJM;
x
2
2=0.005, P=0.997 for JAMA; x
2
2=0.042, P=0.980 for The
Lancet; x
2
2=2.825, P=0.243 for Ann Int Med; and x
2
2=4.755,
P=0.093 for BMJ).
The main characteristics of the selected RCTs from the
ClinicalTrials.gov and articles are presented in Table S2. The
majority of registered RCTs were phase 3 (n=80, 52.6%), placebo
controlled (n=63, 41.4%), double blind (n=85, 55.9%), with
parallel assignment (n=103, 67.8%) and with efficacy and safety
end point (n=75, 49.3%). The most common purpose was
treatment (n=102, 67.1%), with both genders as participants
(n=131, 86.2%). Only 9 (5.9%) RCTs were single-center, the
intervention was mostly a drug (n=100, 65.8%) and more than half
(86, 56.6%) were not sponsored by industry. Finally, most RCTs
(n=96,63.2%)includedboth primaryandsecondaryoutcomesand
were superiority studies (n=130, 85.5%). Positive results were
reported for 77 (50.7%) RCTs, serious adverse events were
published in 131 (86.2%) articles and 7 (4.6%) RCTs were reported
to be stopped early for harm and 3 (2.0%) for benefit.
Figure 1. Flow diagram of RCTs sample selection from all reports of clinical trials with ClinicalTrials.gov registration number
published by ICMJE journals from 13 September 2005 to 24 April 24 2008.
doi:10.1371/journal.pone.0025258.g001
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deadlines
Two thirds of the RCTs (n=101, 66.4%) were registered before
13 September 2005 deadline. In relation to the recruitment status,
118 (77.6%) started before and 31 (20.4%) after the registration.
For 3 (2.0%) RCTs there were no data about the start date in the
registry.
Completeness of Minimum Data Set items in
ClinicalTrials.gov
Out of 152 RCTs, 29 (19.1%) had a single registration point
before the publication and 123 RCTs (80.9%) had 1 or more
changes to the registered data from the first registration to the
publication.
At the time of registration, 152 RCTs had a total of 224 missing
registry fields for 9 WHO Minimum Data Set items (Table 1). For
101 missing registry fields (45.1% of all missing fields), the data
could be found in some other field, mostly in the Detailed
description field of the ClinicalTrials.gov. Most commonly missing
field was ‘Key secondary outcomes’ (44.1% RCTs), followed by
‘Primary outcome’ (38.8% RCTs). For a half of the ‘Key
secondary outcomes’ entries (50.7%) and for more of the three
quarters of the ‘Primary outcomes’ entries (81.3%), the data were
found in other fields (Table 1).
For RCTs with more than 1 change in the registration entries
(n=123), the number of missing items in relevant fields at the last
registration change before publication did not significantly differ
from that at the first registration (chi-square test, P range 0.243–
0.940 for individual registration items). There were no differences
in the number of RCTs registry fields missing at initial registration
at the last change in the registration before publication in
individual journals (Table S3). Similar to the finding at first
registration, the most commonly missing fields in at the last
registration were ‘Key secondary outcomes’ (39.8% RCTs) and
‘Primary outcome’ (34.1% RCTs) and the information on a more
than half of those missing items could be found in other registry
fields (Table 1).
Significantly more RCTs starting recruitment after registration
than RCTs starting recruitment before registration had missing
data about the scientific title of the study, intervention(s), key
inclusion or exclusion criteria, anticipated trial start date, target
sample size, primary outcome or key secondary outcomes. At
initial registration, 57 (48.3%) out of 118 trials starting before and
24 (77.4%) out of 31 trials starting after registration had missing
data for at least one of the registry items (x
2
1=7.255, P=0.007).
At the last change in the registry before publication, 39 (42.4%)
out of 92 trials starting before and 21 (72.4%) out of 29 trials
starting after registration had missing items (x
2
1=6.795,
P=0.009).
Changes in Minimum Data Set items in ClinicalTrials.gov
For 123 RCTs that had recorded changes in the ClinicalTrials.gov
before the publication of the article in the journal, the median
number of all changes (major and minor) was 4 (95% CI 3–5,
range 1 to 38). Major changes were found for 8 out of 9 WHO
Minimum Data Set items (Table 2) and in 31 (25.2%) RCTs
registrations: 16 out of 60 published in N Engl J Med, 9 out of 29 in
The Lancet, 6 out of 33 in JAMA and 3 out of 12 in Ann Intern Med.A
single change was observed for 10 RCTs, mostly concerning the
‘Target sample size’ entries. Out of 21 RCTs with more than 1
change, only in a single case the change did not include primary or
secondary or both outcomes. The changes occurred mostly often
for ‘Primary outcome’, ‘Key secondary outcomes’ and ‘Target
sample size’ entries (Table 2). The changes in the entries for
primary and secondary outcomes occurred at the same time for 19
Table 1. Randomized controlled trials (RCTs) in ClinicalTrials.gov with missing data in the registration fields of 9 WHO Minimum
Data Set items at initial registration and at last change before publication date, and differences of published data to those specified
in the trial registration.
No. (%) of RCTs with missing or misplaced registry data
at initial registration (n=152)
last change before publication date
(n=123){
Minimum Data
Set items*
missing in
relevant
registry field
present in
other registry
field
missing in
relevant
registry field
present in
other registry
field
Reported data vs registry data:
No. (%) of published
RCTs different from
registration (n=152){
10. Official scientific title of the study 26 (17.1) 0 (0.0) 14 (11.4) 0 (0.0) 111 (73.0)
12. Condition 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
13. Intervention(s) 3 (2.0) 3 (2.0) 2 (1.6) 1 (0.8) 113 (74.3)
14. Key inclusion or Key
exclusion criteria
3 (2.0) 0 (0.0) 3 (2.4) 0 (0.0) 44 (28.9)
78 (51.3)
15. Study type 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 21 (13.8)
16. Anticipated trial start date 22 (14.5) 1 (0.6) 8 (6.5) 1 (0.8) 34 (22.4)
17. Target sample size 44 (28.9) 18 (11.8) 36 (29.3) 13 (10.6) 118 (77.6)
19. Primary outcome 59 (38.8) 48 (31.6) 42 (34.1) 35 (28.4) 59 (38.8)
20. Key secondary outcomes 67 (44.1) 34 (22.4) 49 (39.8) 30 (24.4) 98 (64.5)
*WHO Minimum Data Set items relevant for publication and assessment of trial quality. Other 11 items were either general or administrative information, recorded only
in the recruitment period and not routinely published in a journal article.
{29 trials had a single registration entry before publication.
{Difference from the last change in the registration for RCTs with more than 1 registration change or difference from the first registration data for RCTs with a single
registration entry (no change in the registration).
doi:10.1371/journal.pone.0025258.t001
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outcomes also had 1 to 3 other changes at the same time. More
RCTs that registered the trial before patient recruitment
underwent major changes to dataset items then those registered
after the start of the patient recruitment: 20 out of 31 (64.5%) vs.
11 out of 118 (9.3%), respectively (x
2
1=40.103, P,0.001).
Reporting completeness of registered Minimum Data Set
items
The comparison of the data published in journal articles with
either the data from the initial registration or the last registration
change before submission to publication, revealed differences in 8
and no changes in 1 dataset item (Item 12 ‘Condition’) out of 9
analyzed dataset items (Table 1). The number of RCTs with
differences between registered and published data ranged from 21
(13.8%) for ‘Study type’ to 118 (77.6%) for ‘Target sample size’
entries (Table 1). More than half of RCTs had different registry
and publication data for the ‘Intervention(s)’, ‘Official scientific
title of the study’, ‘Key secondary outcomes’ and ‘Key exclusion
criteria’ entries. As shown in Table 3, the differences in the
published data vs. registered items involved clarification of the
entry in the article, especially for the registry entries ‘Official
scientific title of the study’, ‘Intervention(s)’ and ‘Study type’. For
some of the entries, such as ‘Key inclusion and exclusion criteria’
and ‘Primary and Secondary outcomes’, the information in the
article differed considerably from the registered data. The most
common difference was the addition of one or more inclusion or
exclusion criteria and addition of primary or secondary outcomes
that could not be found in the registry.
At the time of analysis in 2008, we found changes in the registry
fields that occurred after the publication of trial results in a journal
(2 in JAMA,3i nThe Lancet and 3 in N Eng J Med). Out of these, 6
were sponsored by industry and all of them involved change in the
registry fields for ‘Primary and/or Secondary outcomes’. In
addition to the ‘Primary and Secondary outcomes’, ‘Scientific
Title’, ‘Start date’ and ‘Sample size’ entries were changed in the
registry for 1 published RCT. For another RCT, there was a
change in ‘Sample size’ and ‘Primary and Secondary outcomes’
(both RCTs were published in The Lancet).
Discussion
Our study demonstrated that the information in the Clinical-
Trials.gov registry was often incomplete for the trials whose results
were published in the ICMJE member journals during the
evaluation period of first 2.5 years after the implementation of
their trial registration policy in 2005. Incompleteness of trial
registration and selective reporting of registered data has been
shown for different subsets of journals and databases [5–8,10–
12,32–33] but our study specifically assessed ICMJE member
journals which were the first to develop and implement the
registration policy. To the best of our knowledge, our study is also
the first one to investigate the changes to the registration up to the
publication of the trial results. Significant changes occurred in
many registry entries between the initial registration and article
publication, including substantive changes to the primary outcome
in 17% and key secondary outcomes in 15% of the trials included
in this study. The number of RCTs with missing or uninformative
information at initial registration decreased at the time of the last
change in the registry before the publication, but this change did
not reach statistical significance. Even at the last registry change
before the publication, more than a third of RCTs had missing
information on primary or secondary outcomes in relevant registry
fields or had this information in other registry fields. Finally,
journal articles on registered trials presented information different
Table 2. Major changes in ClinicalTrials.gov registry fields for 8 WHO Minimum Data Set items in 31 RCTs out of 123 RCTs with one
or more changes in the registry after the initial registration.*
WHO Dataset item Change No. (%) RCTs
Item 10 – Official scientific title of the study Added at last change before publication 11 (8.1)
Item 13 – Intervention(s) Code changed to generic name 1 (0.8)
Item 14 – Inclusion criteria One criterion deleted 1 (0.8)
Item 14 – Exclusion criteria One criterion deleted 1 (0.8)
Item 15 – Study type Changed from ‘‘not applicable’’ to phase 3 1 (0.8)
Item 16 – Anticipated trial start date Added at last change before publication 7
Changed to earlier date 1
Total 8 (6.5)
Item 17 – Target sample size Added at last change before publication 10
Existing entry deleted 1
Total 11 (8.9)
Item 19 – Primary outcome New outcomes added at last change before publication 20
Existing outcome deleted 1
Total 21 (17.0)
Item 20 – Key secondary outcomes New outcomes added at last change before publication 18
Existing outcome deleted 1
Total 19 (15.4)
*Major modification of the registered data was defined as either a qualitative change – difference in the meaning of the information provided in the registry field, or a
quantitative change – difference in the numerical entry in the registry field. For 1 out of 9 evaluated items (Item 12 ‘Health Condition(s) or Problem(s) Studied’), we did
not record any changes.
doi:10.1371/journal.pone.0025258.t002
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ICMJE/WHO Dataset item/change Change No. (%) RCTs
Item 10 – Official scientific title of the study More informative in article then in registry 54
More informative in registry then in article 41
Missing in registry 14
Different in article from registry 2
Total 111 (73.0)
Item 13 – Intervention(s) More informative in article 110
Missing in registry 1
Different in article from registry 2
Total 113 (74.3)
Item 14 – Inclusion criteria New criteria added in article (median 2.0, 95% CI 1.84–2.55) 25
Criteria omitted in article (median 2.0, 95% CI 1.96–2.76) 19
New added and some omitted 2
Missing in registry 1
More informative in article then in registry 1
Total 44 (28.9)
Item 14 – Exclusion criteria New criteria added in article (median 4.0, 95% CI 3.80–6.73) 37
Criteria omitted in article (median 3.5, 95% CI 3.34–5.54) 36
New added and some omitted 4
Missing in registry 9
Total 78 (51.3)
Item 15 – Study type More informative in article then in registry 19
Different in article from registry{ 2
Total 21 (13.8)
Item 16 – Anticipated trial start date Started later (according to date in article vs. in registry) 12
Started earlier (according to date in article vs. in registry) 5
Missing in registry or article 17
Total 34 (22.3)
Item 17 – Target sample size Greater in article then in registry 54
Smaller in article then in registry 32
Missing in registry or article 32
Total 118 (77.6)
Item 19 – Primary outcome{ New outcomes introduced in article 3
Registered outcomes omitted in article 2
Changed to secondary outcome in article 3
Stated in article but missing in registry 46
Newly introduced and reported as secondary 1
Uninformative or not reported separately from secondary outcomes 4
Total 59 (38.8)
Item 20 – Key secondary outcomes{ New outcomes introduced in article 19
Registered outcomes omitted in article 15
Stated in article but missing in registry 48
Outcome used for power calculation in article different from registered 2
Timing of assessment different in article and registry 1
Some newly introduced and some omitted at the same time 3
Combination of newly introduced or omitted outcomes and difference in power
calculation
4
Uninformative or not reported separately 6
Total 98 (64.5)
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lfrom that in the registry for many WHO Minimum Data Set
items, including key secondary outcomes (64% RCTs), target
sample size (78% RCTs), interventions (74% RCTs), exclusion
criteria (51% RCTs) and primary outcome (39% RCTs).
Our study assessed a single registry, ClinicalTrials.gov, which
presents a study limitation. However, at the time when the ICMJE
mandatory registration policy was announced and implemented,
ClinicalTrials.gov was the only registry that fulfilled the ICMJE
criteria [23] and the greatest increase in registered trials around
ICMJE deadline dates was observed for this registry [26]. Another
limitation may be that ClinicalTrials.gov does not necessarily
mandate certain data items that are mandatory in any WHO
primary register [31]. At present, ClinicalTrials.gov is not a member
of the Network of WHO Primary registries but is a data provider
to the ICTRP [31]. A further limitation of the study is its
retrospective design and a small number of RCT registered after
ICMJE deadline and before the recruitment of the first patients
(20.4% of the whole study sample). Also, the analysis included a
random sample of articles from ICMJE journals publishing many
RCTs and all articles from 2 ICMJE journals with small number
of published RCTs, which may have introduced a bias. The
temporal comparison of registration items and changes after
registration was assessed in two time periods, before and after the
ICMJE policy deadlines, so that categorization of the time as a
continuous variable may have introduced a bias in the statistical
analyses. The categorization was used because of the evidence that
the highest RCTs registration volume occurred before the
September 2005 deadline [25]. The same bias may have been
introduced for the analysis of changes in the registry over time
because these were categorized to changes at initial registration
and at last change before publication. We focused on the first two
years after the registration policy implementation because this time
frame was set by the ICMJE as the period for policy evaluation as
a basis for possible future changes to the policy [24]. Our study
period was six months longer then the initial two years because we
considered the first six months after the September 2005 ICMJE
deadline as an adaptation period for sponsors, researchers and
editors. The trial registration landscape has been changing since
the introduction of ICMJE registration requirement [32,35] and
this may have affected our results, as well as any longer follow-up
of registration since the ICMJE registration deadlines in 2005.
Finally, an important limitation of the study could be that the
assessment of registry entries, especially the precision of informa-
tion and qualitative changes in the registry fields during the trial,
was inherently subjective. However, the evaluation of the registry
entries and the published articles was performed by a clinical
pharmacologist (MH) with experience in different types of clinical
trials as well as in reporting standards for RCTs.
We found that significantly more RCTs which started
recruitment after registration had missing registry data in
important WHO Minimum Data Set items at the first registration
and at last change before publication than RCTs which started
recruitment before the registration (ie, RCTs that had to be
registered until ICMJE deadline of 13 September 2005). The
explanation for such finding could be that the researchers or
sponsors who were responsible for the registry data entry had
greater incentive for a more complete registration at the point
when the trial was either well advanced or its results prepared for
a publication then those who had to enter data for a future
trial. This explanation is also supported by our finding that
major changes to the registry entries were more frequent for
RCTs registered before the recruitment then for those registered
after the onset of recruitment. For trials with prospective
registration, although changes to the some registered data are
expected during a trial execution, major changes such as deleting
or adding primary outcomes, as observed in our study, should not
occur.
We found 14 RCTs that declared only a drug code in the
‘Intervention’ registry field and in only 2 of those the code was
changed to a generic name at the last registry change before the
publication. Clearer and more honest reporting is now promoted
by the change to WHO Minimum Data Set requirement for this
item, from the statement ‘‘For an unregistered drug, the generic
name, chemical name, or company serial number is acceptable.’’
[34] to the statement ‘‘For investigational new drugs that do not
yet have a generic name, a chemical name, company code or serial
number may be used on a temporary basis. As soon as the generic
name has been established, update the associated protocol records
accordingly.’’ [35].
At the time of the ICMJE policy implementation, the problems
of data quality in the ClinicalTrials.gov already existed. For example,
Zarin et al [26] reported that out of 2670 studies registered in this
registry between May and October 2005, almost a quarter failed
to enter any information for Item 19 ‘Primary outcome’ and many
had noninformative entries for Item 13 ‘Intervention’. Our study
showed that introduction of the ICMJE policy of providing WHO
Minimum Data Set did not result in better registry data, either for
the trials that had to be only registered before submission to the
journal or the trials that needed registering before the trial onset.
The same was true for other 21 trial registries evaluated from the
period from April 2005 and February 2007 [33].
It is not known whether or how ICMJE editors verified the
compliance with the WHO Minimum Data Set during the period
analyzed in our study. Our journal, the Croatian Medical Journal,i s
an ICMJE member journal and published 5 RCTs during the
investigated period. All RCTs had to be registered to comply with
the 13 September 2005 deadline and we did not check the
adequacy of registration. We are not sure about the practices of
journals with a high number of RCT submissions. The time
around the two deadlines was surely a busy one for editors of such
journals, who had to train the staff as well as train and assist their
authors in implementing the registration policy. One of the
reasons for poor compliance with the WHO Minimum Data Set
during the analyzed period could also be the presentation of
registry elements in the ClinicalTrials.gov at that time, which
included a number of data fields other than the WHO Minimum
Data Set. Only in September 2007, ClinicalTrials.gov introduced the
tabular view of the registry items, where WHO Minimum Data
Set items were clearly indicated by different color [36]. As the
number of RCTs from our study registered and submitted to
*For 1 out of 9 items (Item 12 ‘Health Condition(s) or Problem(s) Studied’), no changes were recorded.
{Studies registered as observational but published as RCTs.
{Classification of changes modified from Chen et al. [8].
doi:10.1371/journal.pone.0025258.t003
Table 3. Cont.
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assess if new features of ClinicalTrials.gov facilitated the editorial
work and increased compliance with the WHO Minimum Data
Set after 2007.
Also, it is not known whether ICMJE (and other) editors
make use of the Archive site of the ClinicalTrials.gov to assess possible
significant changes from the initial trial registration, which could
influence the peer review and editorial decisions. We found
that important registry data in the sample of articles and trial
registrations in our study changed during the registration up to
the journal publication but have no information whether these
changes were addressed and resolved between the authors and
editors during manuscript processing and publication. We ob-
served that the data in the registry for several RCTs changed even
after the publication of trial results and involved changes to the
primary and secondary outcomes. These changes may be related
to the legal requirements for trial results registration, introduced in
September 2007, when Food and Drug Administration Amend-
ments Act (FDAAA) mandated that all phase 2–4 drug and
biological studies with one or more study sites in the United States,
or studies being conducted under a U.S. investigational new drug
application, be registered in ClinicalTrials.gov within 21 days of first
patient enrolment and that trials that were in progress should be
registered by December 2007 [37].
What are the implications of the study results and what can
editors and other stakeholders in clinical research do to improve
the quality of registry data? We believe that the quality assurance
and management cannot be left only to the registries, but that
the journals should continue to carry burden for the transparency
of clinical research. An important step in increasing the
compliance with the WHO Minimum Data Set could be that
ICMJE (and other) journals clearly describe their procedures
for ensuring the full implementation of their registrations
requirement policy, primarily how they ensure that all relevant
fields contain meaningful information, whether they assess the
changes to the registration data and how they handle important
discrepancies. With a powerful tool such as the Archive site of the
ClinicalTrials.gov and other registries and a clear description of
‘sentinel’ procedures to ensure the quality of registered data,
journals may provide strong incentives for authors and sponsors
for better compliance with the WHO Minimum Data Set. We can
envision a trial registration checklist similar to those for reporting
results from different types of research, such as CONSORT [38].
Similar to the CONSORT checklist, peer reviewers could be
asked for quality check with the registration checklist; the final
check of the results in a submitted manuscript against the registry
data would be performed by journal editors. All discrepancies
between the manuscript and the registration data should be
resolved before final approval for publication and addressed in the
manuscript.
In addition to registries and journals, other stakeholders should
contribute to the efforts to ensure that the information on clinical
trials is honest, transparent and accurate. Detailed information on
the WHO Minimum Data Set could be a part of the application
process for trial funding and the approval of the ethics committees
and regulatory authorities, which could perform a quality check of
the registration data planned for a public register before providing
approval for the trial. It is not clear whether researchers doing
systematic reviews of trials use the Archive site but it may provide a
powerful tool for them to check the quality of the data included in
the review. Archiving of changes to the registration should in now
a standard feature for all primary registries within the WHO
ICTRP, where each registry has to provide an audit trail of
changes to trial profiles in order to maintain primary status [31].
From 2010, the checklist of the CONSORT statement includes
the need for specification of any changes to trial outcomes after the
trial commenced, with reasons, as well as where the full trial
protocol can be accessed, if available [38]. ClinicalTrials.gov has also
recently introduced separate registry fields for original and current
primary and secondary outcome measures.
Both the academic and industry researchers may also need
more information about registration standards before they are
expected to comply with the current requirements. A survey
of academic researchers about their opinion regarding the
registration of study details showed that only 31% were willing
to disclose study document, particularly study protocols and
financial agreements [39]. Another survey showed that 62% trial
researchers with non-industry funding and 42% researchers
with mixed or only industry funding would always provide the
WHO Minimum Data Set to a public registry for future clinical
trials [40].
Our study and the recent evaluation of the compliance of
21 trial registries with the WHO Minimum Data Set [33] show
that there is a need for standardization of mandatory dataset
items across the registries and in collaboration with the ICMJE.
Registry items that differ or are missing from registries, such as
ethics committee approval, regulatory authority approval, assess-
ment of adverse event, funding source, should be standardized
in order to improve quality and completeness of subsequent
publications. For example, the WHO Minimum Data Set does
not include statement on assessing adverse events (AE), although
in the sample of the RCTs analyzed in our study, serious and
non-serious AEs were mentioned in more than 80% of the
published articles. Several studies have documented underreport-
ing of low-grade AEs, underreporting of recurrent AEs and
inconsistent and incomplete characterization and reporting of
high-grade AEs [10–12]. Introducing entries addressing safety
issues in relation to registered outcome measures could be the
solution to this problem. Trial registries also contain limited
methodological information such as random sequence generation,
allocation concealment, sample size calculation, all important
for critical appraisal of trial results [41]. These are not manda-
tory items of the WHO Minimum Data Set or ICMJE require-
ments. The WHO ICTRP has recently introduced a number of
measures to improve the quality of registered data, such as
improvement of explanatory text on trail registration data set and
establishment of International Standards for Clinical Trial
Registries [42].
In conclusion, although the introduction of ICMJE registration
policy increased the visibility of clinical trials, there is a need for
further improvement of quality control procedures in the journals
so that they continue to lead the improvements in the transparency
of clinical trials. We hope that our assessment of the first two years
of the registration policy implementation would provide evidence
for the ICMJE to assess the structures and procedures it has now in
place so that the outcomes of the trial registration policy could be
further improved.
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